Details of Drug-Drug Interaction
| Drug General Information (ID: DDIB956WQH) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Elagolix | Drug Info | Prasterone enantate | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Gonadotropin-Releasing Hormone Antagonists | Androgens | |||||||
| Structure | |||||||||
| Mechanism of Elagolix-Prasterone enantate Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Elagolix | Prasterone enantate | |||||||
| Mechanism | Elagolix | Decrease the therapeutic efficacy of elagolix | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacodynamics | ||||||||
| Factor Description | Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Women requiring contraception should be advised to use non-hormonal forms of contraception during treatment with elagolix and for one week after its discontinuation. | ||||||||